Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 3.69
BIIB's Cash to Debt is ranked higher than
63% of the 1493 Companies
in the Global Biotechnology industry.

( Industry Median: 48.04 vs. BIIB: 3.69 )
BIIB' s 10-Year Cash to Debt Range
Min: 0.25   Max: N/A
Current: 3.69

Equity to Asset 0.77
BIIB's Equity to Asset is ranked higher than
79% of the 1113 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. BIIB: 0.77 )
BIIB' s 10-Year Equity to Asset Range
Min: 0.52   Max: 0.85
Current: 0.77

0.52
0.85
Interest Coverage 134.09
BIIB's Interest Coverage is ranked higher than
54% of the 680 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIIB: 134.09 )
BIIB' s 10-Year Interest Coverage Range
Min: 2.3   Max: 9999.99
Current: 134.09

2.3
9999.99
F-Score: 9
Z-Score: 18.65
M-Score: -2.25
WACC vs ROIC
6.82%
36.03%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 10/10

vs
industry
vs
history
Operating margin (%) 43.46
BIIB's Operating margin (%) is ranked higher than
98% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -79.37 vs. BIIB: 43.46 )
BIIB' s 10-Year Operating margin (%) Range
Min: -128.05   Max: 52.91
Current: 43.46

-128.05
52.91
Net-margin (%) 32.36
BIIB's Net-margin (%) is ranked higher than
96% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. BIIB: 32.36 )
BIIB' s 10-Year Net-margin (%) Range
Min: -128.85   Max: 36.64
Current: 32.36

-128.85
36.64
ROE (%) 31.76
BIIB's ROE (%) is ranked higher than
98% of the 1371 Companies
in the Global Biotechnology industry.

( Industry Median: -28.22 vs. BIIB: 31.76 )
BIIB' s 10-Year ROE (%) Range
Min: -21.44   Max: 31.98
Current: 31.76

-21.44
31.98
ROA (%) 23.96
BIIB's ROA (%) is ranked higher than
98% of the 1497 Companies
in the Global Biotechnology industry.

( Industry Median: -22.65 vs. BIIB: 23.96 )
BIIB' s 10-Year ROA (%) Range
Min: -15.14   Max: 24.62
Current: 23.96

-15.14
24.62
ROC (Joel Greenblatt) (%) 180.56
BIIB's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. BIIB: 180.56 )
BIIB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -62.79   Max: 211.79
Current: 180.56

-62.79
211.79
Revenue Growth (3Y)(%) 25.70
BIIB's Revenue Growth (3Y)(%) is ranked higher than
90% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. BIIB: 25.70 )
BIIB' s 10-Year Revenue Growth (3Y)(%) Range
Min: -13.9   Max: 84.7
Current: 25.7

-13.9
84.7
EBITDA Growth (3Y)(%) 31.90
BIIB's EBITDA Growth (3Y)(%) is ranked higher than
92% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. BIIB: 31.90 )
BIIB' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -16.4   Max: 86
Current: 31.9

-16.4
86
EPS Growth (3Y)(%) 34.90
BIIB's EPS Growth (3Y)(%) is ranked higher than
94% of the 824 Companies
in the Global Biotechnology industry.

( Industry Median: -4.80 vs. BIIB: 34.90 )
BIIB' s 10-Year EPS Growth (3Y)(%) Range
Min: -66   Max: 205.2
Current: 34.9

-66
205.2
» BIIB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

BIIB Guru Trades in Q2 2014

Louis Moore Bacon 32,500 sh (New)
Jim Simons 129,261 sh (New)
Stanley Druckenmiller 103,800 sh (New)
Ken Fisher 88,885 sh (+386.61%)
Jeremy Grantham 857,799 sh (+79.83%)
Ron Baron 8,632 sh (+41.76%)
Mario Gabelli 4,175 sh (+16.46%)
Frank Sands 4,891,463 sh (+0.38%)
Bill Frels 1,125 sh (unchged)
Steven Cohen 7,600 sh (unchged)
Murray Stahl 8,493 sh (unchged)
George Soros Sold Out
Joel Greenblatt Sold Out
Andreas Halvorsen Sold Out
John Burbank Sold Out
Caxton Associates Sold Out
Ken Heebner Sold Out
PRIMECAP Management 17,258,311 sh (-1.39%)
Pioneer Investments 1,232 sh (-1.52%)
Vanguard Health Care Fund 559,700 sh (-6.62%)
RS Investment Management 16,250 sh (-8.04%)
Paul Tudor Jones 899 sh (-72.75%)
» More
Q3 2014

BIIB Guru Trades in Q3 2014

Ray Dalio 1,646 sh (New)
Ken Heebner 80,000 sh (New)
Joel Greenblatt 31,391 sh (New)
Paul Tudor Jones 3,061 sh (+240.49%)
RS Investment Management 20,205 sh (+24.34%)
Mario Gabelli 4,635 sh (+11.02%)
Bill Frels 1,170 sh (+4.00%)
Frank Sands 4,952,096 sh (+1.24%)
Stanley Druckenmiller 103,800 sh (unchged)
Pioneer Investments 1,069 sh (unchged)
Steven Cohen Sold Out
Louis Moore Bacon Sold Out
Ron Baron 8,613 sh (-0.22%)
PRIMECAP Management 17,216,631 sh (-0.24%)
Murray Stahl 8,468 sh (-0.29%)
Jeremy Grantham 800,301 sh (-6.70%)
Ken Fisher 78,457 sh (-11.73%)
Jim Simons 92,661 sh (-28.31%)
Vanguard Health Care Fund 233,600 sh (-58.26%)
» More
Q4 2014

BIIB Guru Trades in Q4 2014

Pioneer Investments 18,593 sh (+1639.29%)
Ray Dalio 15,146 sh (+820.17%)
Paul Tudor Jones 27,786 sh (+807.74%)
Stanley Druckenmiller 359,400 sh (+246.24%)
Mario Gabelli 4,935 sh (+6.47%)
Ron Baron 9,144 sh (+6.17%)
Ken Fisher 79,254 sh (+1.02%)
Murray Stahl 8,517 sh (+0.58%)
Frank Sands 4,974,331 sh (+0.45%)
Frank Sands 4,974,331 sh (+0.45%)
Vanguard Health Care Fund Sold Out
Ken Heebner Sold Out
PRIMECAP Management 17,170,693 sh (-0.27%)
Bill Frels 1,140 sh (-2.56%)
Jeremy Grantham 696,116 sh (-13.02%)
Jim Simons 65,161 sh (-29.68%)
Joel Greenblatt 5,012 sh (-84.03%)
RS Investment Management 1,218 sh (-93.97%)
» More
Q1 2015

BIIB Guru Trades in Q1 2015

Richard Snow 2,500 sh (New)
John Burbank 46,268 sh (New)
Vanguard Health Care Fund 339,100 sh (New)
Steven Cohen 8,800 sh (New)
RS Investment Management 27,197 sh (+2132.92%)
Ray Dalio 20,446 sh (+34.99%)
Ken Fisher 81,058 sh (+2.28%)
Frank Sands 5,009,615 sh (+0.71%)
Ron Baron 9,144 sh (unchged)
Joel Greenblatt Sold Out
Mario Gabelli 4,932 sh (-0.06%)
Pioneer Investments 18,472 sh (-0.65%)
Murray Stahl 8,448 sh (-0.81%)
Bill Frels 1,120 sh (-1.75%)
PRIMECAP Management 16,558,763 sh (-3.56%)
Jeremy Grantham 669,145 sh (-3.87%)
Stanley Druckenmiller 175,000 sh (-51.31%)
Jim Simons 30,300 sh (-53.50%)
Paul Tudor Jones 4,880 sh (-82.44%)
» More
» Details

Insider Trades

Latest Guru Trades with BIIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Biogen Inc

Ken Fisher's Top Increases of the Second Quarter
CEO and CIO of Fisher Investments and regular Forbes contributor, Ken Fisher, had a pretty busy second quarter. Fisher purchased a total of 50 new stocks. His second quarter portfolio holds 558 stocks and is valued at over $47.56 billion. The following five stocks represent the five companies where Fisher made the largest increase in holdings during the second quarter. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 28.80
BIIB's P/E(ttm) is ranked higher than
95% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 28.80 )
BIIB' s 10-Year P/E(ttm) Range
Min: 11.74   Max: 1121.33
Current: 28.8

11.74
1121.33
Forward P/E 19.38
BIIB's Forward P/E is ranked higher than
94% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 19.38 )
N/A
PE(NRI) 28.80
BIIB's PE(NRI) is ranked higher than
95% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 28.80 )
BIIB' s 10-Year PE(NRI) Range
Min: 11.73   Max: 1085.16
Current: 28.8

11.73
1085.16
P/B 8.05
BIIB's P/B is ranked higher than
60% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. BIIB: 8.05 )
BIIB' s 10-Year P/B Range
Min: 1.74   Max: 9.61
Current: 8.05

1.74
9.61
P/S 9.31
BIIB's P/S is ranked higher than
78% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 40.71 vs. BIIB: 9.31 )
BIIB' s 10-Year P/S Range
Min: 2.8   Max: 12.16
Current: 9.31

2.8
12.16
PFCF 29.14
BIIB's PFCF is ranked higher than
96% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 29.14 )
BIIB' s 10-Year PFCF Range
Min: 10.04   Max: 479.77
Current: 29.14

10.04
479.77
POCF 26.42
BIIB's POCF is ranked higher than
95% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 26.42 )
BIIB' s 10-Year POCF Range
Min: 7.83   Max: 43.31
Current: 26.42

7.83
43.31
EV-to-EBIT 20.95
BIIB's EV-to-EBIT is ranked higher than
96% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 20.95 )
BIIB' s 10-Year EV-to-EBIT Range
Min: -21.4   Max: 585.7
Current: 20.95

-21.4
585.7
PEG 1.13
BIIB's PEG is ranked higher than
99% of the 1654 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 1.13 )
BIIB' s 10-Year PEG Range
Min: 0.33   Max: 2.56
Current: 1.13

0.33
2.56
Shiller P/E 56.75
BIIB's Shiller P/E is ranked higher than
95% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 56.75 )
BIIB' s 10-Year Shiller P/E Range
Min: 24.2   Max: 1337
Current: 56.75

24.2
1337
Current Ratio 2.70
BIIB's Current Ratio is ranked higher than
64% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.49 vs. BIIB: 2.70 )
BIIB' s 10-Year Current Ratio Range
Min: 0.78   Max: 17.39
Current: 2.7

0.78
17.39
Quick Ratio 2.28
BIIB's Quick Ratio is ranked higher than
63% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. BIIB: 2.28 )
BIIB' s 10-Year Quick Ratio Range
Min: 0.7   Max: 16.79
Current: 2.28

0.7
16.79
Days Inventory 228.61
BIIB's Days Inventory is ranked higher than
81% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 228.61 )
BIIB' s 10-Year Days Inventory Range
Min: 69.41   Max: 10720.03
Current: 228.61

69.41
10720.03
Days Sales Outstanding 50.09
BIIB's Days Sales Outstanding is ranked higher than
88% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 141.98 vs. BIIB: 50.09 )
BIIB' s 10-Year Days Sales Outstanding Range
Min: 4.44   Max: 106.69
Current: 50.09

4.44
106.69

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 55.07
BIIB's Price/Net Current Asset Value is ranked higher than
58% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 48.94 vs. BIIB: 55.07 )
BIIB' s 10-Year Price/Net Current Asset Value Range
Min: 0.59   Max: 789.6
Current: 55.07

0.59
789.6
Price/Tangible Book 17.19
BIIB's Price/Tangible Book is ranked higher than
50% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 10.70 vs. BIIB: 17.19 )
BIIB' s 10-Year Price/Tangible Book Range
Min: 1.9   Max: 25.38
Current: 17.19

1.9
25.38
Price/DCF (Projected) 3.42
BIIB's Price/DCF (Projected) is ranked higher than
95% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 3.42 )
BIIB' s 10-Year Price/DCF (Projected) Range
Min: 0.65   Max: 25.99
Current: 3.42

0.65
25.99
Price/Median PS Value 1.52
BIIB's Price/Median PS Value is ranked higher than
76% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. BIIB: 1.52 )
BIIB' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 12.66
Current: 1.52

0.12
12.66
Price/Peter Lynch Fair Value 1.15
BIIB's Price/Peter Lynch Fair Value is ranked higher than
99% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 1.15 )
BIIB' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.44   Max: 20.5
Current: 1.15

0.44
20.5
Price/Graham Number 4.67
BIIB's Price/Graham Number is ranked higher than
91% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 4.67 )
BIIB' s 10-Year Price/Graham Number Range
Min: 0.43   Max: 21.27
Current: 4.67

0.43
21.27
Earnings Yield (Greenblatt) 4.80
BIIB's Earnings Yield (Greenblatt) is ranked higher than
95% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. BIIB: 4.80 )
BIIB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 12
Current: 4.8

0.2
12
Forward Rate of Return (Yacktman) 28.50
BIIB's Forward Rate of Return (Yacktman) is ranked higher than
90% of the 189 Companies
in the Global Biotechnology industry.

( Industry Median: 14.92 vs. BIIB: 28.50 )
BIIB' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.8   Max: 43.9
Current: 28.5

0.8
43.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, CELG, CMXHY » details
Traded in other countries:IDP.Germany, BIIB.Mexico, BIIB.Switzerland,
Biogen Idec Inc was formed as a California corporation in 1985 and became a Delaware corporation in 1985. The Company is a biotechnology company. It discovers, develops, manufactures and markets therapies for the treatment of autoimmune disorders, neurodegenerative diseases and hemophilia. It also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions. The Company's marketed products include MA Products, AVONEX; TYSABRI; RITUXAN; FAMPYRA; FUMADERM. The Company develop, manufacture and market a number of products designed to treat patients with MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve cells, to a loss of muscle control, paralysis and, in some cases, death. AVONEX is one of the prescribed treatments for relapsing forms of MS. TYSABRI has advanced the treatment of relapsing MS with its established efficacy. TYSABRI is a monoclonal antibody approved in numerous countries as a monotherapy treatment for relapsing MS and also approved in the U.S. to treat Crohn's disease, an inflammatory disease of the intestines. RITUXAN is a prescribed monoclonal antibody therapeutic used to treat non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia and two forms of ANCA-associated vasculitis. FAMPYRA is the first treatment that addresses the unmet medical need of walking improvement in adult patients with MS who have walking disability. FAMPYRA is a prolonged-release tablet formulation of the drug fampridine. The Company is facing competition from other biotechnology firms and large pharmaceutical companies. The Company is subject to various federal and state laws pertaining to health care fraud and abuse, including anti-kickback laws and false claims laws.
» More Articles for BIIB

Headlines

Articles On GuruFocus.com
8 Top Healthcare Stocks to Watch May 13 2015 
Biogen Making A Breakthrough In Treating Alzheimer’s May 02 2015 
Vanguard Healthcare Fund Adds Four New Positions May 01 2015 
Biogen or Bluebird: Which Will Lead in SCD? Apr 30 2015 
Analysts Provide Update for Biogen, PTC Therapeutics, GW Pharma, and Isis Pharma Apr 22 2015 
Biogen And Idec To Part Ways After Inventing Alzheimer's Drug Mar 27 2015 
Biogen’s Alzheimer’s Drug Shows Promising Test Results Mar 23 2015 
Biogen Idec (BIIB) At All-time High Levels, KB Home (KBH) Revenue Growth Trajectory, Ctrip (CTRP) Re Mar 23 2015 
The Best Upcoming Dividend Stocks Mar 20 2015 
This Week’s Pharma Highlights Mar 19 2015 

More From Other Websites
A Beautiful Biotech Summer? May 22 2015
BlueBird Bio: Another Biogen Rout In The Making? May 21 2015
Jim Cramer Answers Your Twitter Questions on Tesla, Jarden, Williams-Sonoma, Wayfair May 21 2015
Biogen to Present at Bernstein’s 31st Annual Strategic Decisions Conference May 20 2015
3 Things Biogen's Management Wants You to Know May 19 2015
Value plays in health care, financials & tech May 19 2015
Good year for stock pickers: Pro May 19 2015
Billionaire Stanley Druckenmiller’s Top Value Picks Include Illumina, Inc. (ILMN), Biogen Inc... May 19 2015
3 Best Biotech Stocks to Add to Your Portfolio May 19 2015
Is the Stock Market Due for a Correction? May 18 2015
The Morning Download: Hardware Advances Bring Deep Learning, Real-Time Analytics Closer to... May 15 2015
Fidelity Adds to Biogen, Amazon and Sells Microsoft, Amex May 14 2015
Buy Microsoft, Biogen for Performance, Avoid Consumer Discretionary Stocks May 14 2015
Biogen Promotes Former Dell Exec as CIO to 'Drive Innovation' May 14 2015
Biogen to Present at the 2015 UBS Global Healthcare Conference May 13 2015
3 Biotech Stocks See Growing Short Interest May 13 2015
Biogen Names Matt Griffiths as Chief Information Officer May 13 2015
Biogen Names Matt Griffiths as Chief Information Officer May 13 2015
Short Sellers Start to Get Nervous on Biotech May 12 2015
Is This Biogen's Next Billion-Dollar Blockbuster? May 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK